Maxinovel Pty., Ltd.

Ownership
Private
Employees
-
Market Cap
-
Website

A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors

Phase 1
Not yet recruiting
Conditions
First Posted Date
2022-06-21
Last Posted Date
2022-06-21
Lead Sponsor
Maxinovel Pty., Ltd.
Target Recruit Count
108
Registration Number
NCT05425602

A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer

First Posted Date
2022-05-27
Last Posted Date
2022-06-02
Lead Sponsor
Maxinovel Pty., Ltd.
Target Recruit Count
30
Registration Number
NCT05395780
Locations
🇨🇳

Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jingsu, China

A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors

First Posted Date
2022-05-11
Last Posted Date
2022-05-11
Lead Sponsor
Maxinovel Pty., Ltd.
Target Recruit Count
28
Registration Number
NCT05369286
Locations
🇨🇳

Institute of The Sixth Affiliated Hospital Sun Yat-sen University, Guangzhou, Guangdong, China

MAX-10181 in Patients With Advanced Solid Tumor

Phase 1
Conditions
Interventions
First Posted Date
2022-01-19
Last Posted Date
2022-01-19
Lead Sponsor
Maxinovel Pty., Ltd.
Target Recruit Count
80
Registration Number
NCT05196360
Locations
🇨🇳

The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China

A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects

Phase 1
Conditions
Interventions
First Posted Date
2022-01-19
Last Posted Date
2022-01-19
Lead Sponsor
Maxinovel Pty., Ltd.
Target Recruit Count
78
Registration Number
NCT05196711

A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer

First Posted Date
2021-11-22
Last Posted Date
2021-12-06
Lead Sponsor
Maxinovel Pty., Ltd.
Target Recruit Count
130
Registration Number
NCT05130021
Locations
🇨🇳

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Phase 1
Conditions
Interventions
First Posted Date
2019-12-05
Last Posted Date
2022-01-19
Lead Sponsor
Maxinovel Pty., Ltd.
Target Recruit Count
30
Registration Number
NCT04187495
Locations
🇨🇳

The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China

MAX-40279-01 in Patients With Advanced Solid Tumors

Phase 1
Conditions
Interventions
First Posted Date
2019-12-03
Last Posted Date
2022-01-19
Lead Sponsor
Maxinovel Pty., Ltd.
Target Recruit Count
30
Registration Number
NCT04183764
Locations
🇨🇳

The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China

MAX-10181 Given Orally to Patients With Advanced Solid Tumor

Phase 1
Conditions
Interventions
First Posted Date
2019-10-10
Last Posted Date
2022-01-19
Lead Sponsor
Maxinovel Pty., Ltd.
Target Recruit Count
30
Registration Number
NCT04122339
Locations
🇦🇺

Linear Clinical Research, Nedlands, Western Australia, Australia

© Copyright 2024. All Rights Reserved by MedPath